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Abstract 
Introduction: The rise of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTI) threatens 
antiretroviral therapy’s long-term success (ART). NNRTIs will remain an essential drug for the management of HIV-1 
due to safety concerns associated with integrase inhibitors. We fitted a dynamic transmission model to historical data 
from 2000 to 2018 in nine countries of southern Africa to understand the mechanisms that have shaped the HIV-1 
epidemic and the rise of pretreatment NNRTI resistance.
Methods: We included data on HIV-1 prevalence, ART coverage, HIV-related mortality, and survey data on pretreat-
ment NNRTI resistance from nine southern Africa countries from a systematic review, UNAIDS and World Bank. Using 
a Bayesian hierarchical framework, we developed a dynamic transmission model linking data on the HIV-1 epidemic 
to survey data on NNRTI drug resistance in each country. We estimated the proportion of resistance attributable to 
unregulated, off-programme use of ART. We examined each national ART programme’s vulnerability to NNRTI resist-
ance by defining a fragility index: the ratio of the rate of NNRTI resistance emergence during first-line ART over the 
rate of switching to second-line ART. We explored associations between fragility and characteristics of the health 
system of each country.
Results: The model reliably described the dynamics of the HIV-1 epidemic and NNRTI resistance in each country. 
Predicted levels of resistance in 2018 ranged between 3.3% (95% credible interval 1.9–7.1) in Mozambique and 25.3% 
(17.9–33.8) in Eswatini. The proportion of pretreatment NNRTI resistance attributable to unregulated antiretroviral 
use ranged from 6% (2–14) in Eswatini to 64% (26–85) in Mozambique. The fragility index was low in Botswana (0.01; 
0.0–0.11) but high in Namibia (0.48; 0.16–10.17), Eswatini (0.64; 0.23–11.8) and South Africa (1.21; 0.83–9.84). The 
combination of high fragility of ART programmes and high ART coverage levels was associated with a sharp increase 
in pretreatment NNRTI resistance.
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Introduction
The rising prevalence of HIV-1 drug resistance is threat-
ening the success of combination antiretroviral therapy 
(ART) programmes in southern Africa and beyond. 
This region has the highest burden of HIV-1 infection, 
accounting for about 30% of persons living with HIV-1 
(PLHIV) globally [1, 2]. Since the early 2000s, first-line 
ART consisting of one non-nucleoside reverse-tran-
scriptase inhibitor (NNRTI) and two nucleoside reverse-
transcriptase inhibitors (NRTIs) was introduced through 
national access programmes [3]. As of 2019, an estimated 
72% of adults living with HIV-1 in the region were treated 
with ART [4].
A substantial increase in HIV-1 drug resistance fol-
lowed the scale-up of ART [5], compounded by limited 
access to resistance testing and low rates of switching to 
second-line ART (based on protease inhibitors) [6]. Drug 
resistance is associated with poor virological, immu-
nological, and clinical outcomes [7–9]. Defined as the 
proportion of PLHIV with resistance mutations before 
or at the time of ART initiation, the prevalence of pre-
treatment resistance is commonly used to monitor resist-
ance in a population. The prevalence of pretreatment 
NNRTI resistance in 2016 was estimated at 11.0% in 
southern Africa [10]. While NNRTIs are being replaced 
by the integrase inhibitor dolutegravir in this region and 
elsewhere, NNRTIs will likely remain an essential drug 
for the management of HIV-1, considering the adverse 
effects and unconfirmed safety concerns associated with 
DTG [11–13]. Also, there is a risk of DTG resistance, 
such as in PLHIV who switch to DTG-based ART with 
an unsuppressed viral load [14, 15]. A better understand-
ing of the factors that led to the level of NNRTI resist-
ance observed in a country could be critical to control 
future DTG resistance.
Several factors influence the growth of pretreatment 
NNRTI resistance. First, de novo resistance mutations 
can emerge in PLHIV on first-line ART who do not sup-
press viral replication [16, 17]. Of note, multi-class drug 
resistance is common even with the modern nucleoside 
reverse transcriptase inhibitor (NRTI) tenofovir [18, 19]. 
Resistance to NNRTIs is facilitated by their long half-
lives and the fact that single nucleotide substitutions 
can result in high-level NNRTI resistance and NNRTI 
cross-resistance [16, 20, 21]. Virological failure may be 
precipitated by suboptimal HIV service delivery, includ-
ing poor adherence support and retention on ART or 
unreliable drug supply, by inappropriate, off-programme 
antiretroviral use or single-drug regimens used for the 
prevention of mother-to-child transmission (PMTCT) 
[22]. Second, the many PLHIV on first-line ART induce 
a selective advantage of drug-resistant HIV-1 strains over 
sensitive strains, with increased transmission during 
virological failure [5, 17, 23]. Third, the dynamic of the 
HIV-1 epidemic in a country might influence exposure 
to NNRTI-resistant strains, and the evolution of pre-
treatment NNRTI resistance. Mathematical models can 
contribute to a better understanding of the mechanisms 
that shape the HIV-1 epidemic and the rise of pretreat-
ment NNRTI resistance in a country and thus inform 
policy. We fitted a dynamic transmission model of HIV-1 
to data on the HIV-1 epidemic and pretreatment NNRTI 
resistance from nine countries in southern Africa using 
a hierarchical Bayesian framework. For each country, we 
estimated the evolution of pretreatment NNRTI resist-
ance with time. We quantified the proportion of pretreat-
ment resistance that can be attributed to off-programme 
antiretroviral use. We estimated an index of fragility 
regarding NNRTI resistance for each national ART pro-
gramme, thus quantifying a country programme’s ability 
to minimise pretreatment NNRTI resistance. We then 
explored associations between the fragility index and 
characteristics of health systems.
Methods
Data
We updated a systematic review of pretreatment 
drug resistance surveys in HIV-1-infected adults 
(aged > 15  years) in low- and middle-income countries 
[10]. The review included publications and abstracts pub-
lished from Jan 1, 2001, to Dec 31, 2016, and unpublished 
data from surveys supported by the World Health Organ-
ization (WHO). We updated the review for the period 
from Jan 1, 2017, to Jul 31, 2019, in PubMed, Embase and 
WHO reports using the same search strategy (Additional 
file 1: Appendix pp 2–4).
We screened studies for eligibility based on title and 
abstract. Eligible studies had to report original survey 
data about the proportion of NNRTI resistance in a sam-
ple of adults (> 15  years) before or at the time of ART 
Conclusions: This comparison of nine countries shows that pretreatment NNRTI resistance can be controlled despite 
high ART coverage levels. This was the case in Botswana, Mozambique, and Zambia, most likely because of better HIV 
care delivery, including rapid switching to second-line ART of patients failing first-line ART.
Keywords: HIV drug resistance, Epidemiology, Southern Africa, Antiretroviral therapy, Health system science, 
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initiation. The data had to be collected between 2000 and 
2018 in one or several of the nine countries of southern 
Africa (Botswana, Eswatini, Lesotho, Malawi, Mozam-
bique, Namibia, South Africa, Zambia, and Zimbabwe). 
Two independent reviewers (JR and CD) assessed the 
full manuscripts of potentially eligible studies. We used 
data from 56 surveys of pretreatment NNRTI resistance 
from southern Africa that were identified in the original 
review. The updated search yielded 1,039 items, lead-
ing to eight additional eligible studies. In total, we thus 
included data from 64 surveys of pretreatment NNRTI 
resistance in nine countries (56 from the original review 
and 8 from the update), for a total of 14,567 individuals.
For each country, we obtained data describing the 
HIV-1 epidemic for each year from 2000 to 2018: (i) 
the number of adults living with HIV, (ii) the number of 
adults living with HIV-1 receiving ART, (iii) the number 
of AIDS-related deaths among adults, and (iv) the size 
of the adult population. Data used in this analysis were 
not raw data from individual patients but aggregated 
data [4, 24]. They were aggregated at the country level as 
reported by UNAIDS and the World Bank.
Model
We developed a dynamic transmission model linking 
the country-specific data on the HIV-1 epidemic to sur-
vey data on NNRTI drug resistance in each country. The 
model consists of a system of ordinary differential equa-
tions with six compartments (Fig. 1), with the following 
features:
• HIV-1 transmission. The force of infection of drug-
sensitive and drug-resistant HIV-1 strains depends 
on the transmission rate β . We assumed that only 
individuals without treatment (compartments I and 
J  ) or who fail first-line treatment (compartment U ) 
can transmit HIV-1 [25], and that there is no fitness 
cost associated with the transmission of drug-resist-
ant strains [26].
• First-line NNRTI-based ART . Untreated individu-
als initiate first-line ART at a time-dependent rate 
τ f (t, ν, ξ) , where the maximal treatment rate τ is 
scaled by a sigmoid function f (t, ν, ξ) to reflect the 
progressive rollout of ART.
• Emergence of de novo NNRTI resistance. HIV-1 
infected adults on first-line ART can acquire de novo 
NNRTI resistance at rate ω.
• Initial levels of pretreatment NNRTI resistance. 
We defined the starting date of the model in 1999, 
before the implementation of ART programmes. We 
describe the level of pretreatment NNRTI resistance 
at that date by an intercept parameter ι . Similar to the 
intercept in a general linear model, this parameter 
describes the proportion of resistance not explained 
by the rollout of ART within ART programmes, fix-
ing the treatment rate at 0.
• Second-line NNRTI-free ART . Individuals who fail 
first-line ART due to NNRTI resistance may be 
switched to second-line NNRTI-free ART regimens 
at rate κ.
• Demography. New individuals enter the adult pop-
ulation (> 15 years) at rate η . All individuals can die 
from background mortality at rate µ , which we fix 
to the inverse of the life expectancy in adults in each 
country. HIV-1 infected individuals without treat-
ment (compartments I and J  ) or who fail first-line 
ART (compartment U ) die from AIDS-related mor-
tality at rate δ.
We used the model to estimate two country-level indi-
cators of pretreatment NNRTI resistance:
• Pretreatment NNRTI resistance unrelated to ART 
programmes. This indicator is defined as ι/PDR2018 , 
where the numerator is the intercept of pretreatment 
NNRTI resistance in the country, and the denomi-
nator the predicted level of pretreatment NNRTI 
resistance in 2018. It quantifies the relative impact 
of unregulated, off-programme antiretroviral use 
or single-drug regimens used for the prevention of 
mother-to-child transmission (PMTCT) on pretreat-
ment NNRTI resistance in a country.
• Fragility of national ART programmes. This indica-
tor reflects the ability of a country’s ART programme 
to minimise the rise in pretreatment drug resistance. 
It is measured by the ratio of ω , i.e. the rate of occur-
rence of NNRTI resistance in adults on first-line ART 
over κ , i.e. the rate of switching to second-line ART. 
It is a proxy measure for the growth of pretreatment 
NNRTI resistance in a country resulting from first-
line ART rollout. It is not dependent on the scale and 
timing of the ART rollout and directly comparable 
across countries. High values (relatively slow switch 
to second-line ART and relatively rapid occurrence of 
NNRTI resistance) indicate fragile ART programmes. 
Low values (relatively rapid switch to second-line 
ART and relatively slow occurrence of NNRTI resist-
ance) describe ART programmes that are resilient 
against the emergence of pretreatment NNRTI resist-
ance. In this framework, differences in delays to 
virological failure detection across countries would 
translate into differences in the fragility index that we 
propose.
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Fig. 1 Structure of the dynamic model of HIV-1 transmission, ART rollout and resistance emergence (upper panel), and model outputs with colours 
corresponding to Figs. 2 and 3 (lower panel). The population is split into six compartments: susceptible to HIV-1 ( S ); infected with a drug-sensitive 
strain and either untreated ( I  ) or treated with first-line ART ( T  ); infected with a drug-resistant strain and either untreated ( J ), treated with first-line 
ART ( U ) or treated with second-line ART ( V  ). The model has ten parameters: transmission rate β ; maximal treatment rate τ scaled by a sigmoid 
function f (t , ν , ξ) (controlled by two parameters for shift ν and slope ξ ); rate at which de novo NNRTI resistance emerges during treatment ( ω ); rate 
of switching to second-line ART ( κ ); rate of AIDS-related mortality ( δ ); rate of background mortality ( µ ); rate of population growth ( η ); and the initial 
proportion of NNRTI resistance ι (not shown)
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Bayesian hierarchical framework
We implemented the model in the Bayesian statistical 
software Stan 2.18.2 [27]. The ODEs for each country 
were numerically integrated in parallel, with a starting 
date in 1999. There were nine free model parameters 
{β , τ , ξ , ν,ω, κ , δ, η, ι} and one fixed parameter µ for each 
country. We imposed a hierarchical structure on the 
parameters related to NNRTI resistance ( ω and ι ). The 
other parameters were independently estimated for each 
country. We selected weakly-informative prior distribu-
tions for all free parameters and conducted prior predic-
tive checks to ensure that the chosen priors limited the 
range of explored parameter space to sensible values [28]. 
By fitting the full hierarchical model to all available data, 
we obtained the joint posterior distribution for the nine 
free model parameters in each country. Further details 
are available in Additional file 1: Appendix, pp 4–8.
Socio-economic variables
We explored associations between the fragility index of 
ART programmes to pretreatment NNRTI resistance and 
seven country-level variables measuring characteristics 
of health systems and countries: (i) pregnant women who 
received NNRTIs for PMTCT as a proportion of HIV-1 
adult prevalence, (ii) total health expenditure per capita 
(in $ purchasing power parity), (iii) the proportion of 
international donor funding in total health expenditure, 
(iv) proportion of out-of-pocket health expenditure, (v) 
gross national income per capita (in $), (vi) proportion 
of rural population, (vii) proportion of unemployed. Data 
were retrieved from the World Bank or UNAIDS [4, 24]. 
We used the mean over the years 2000 to 2018 for this 
analysis. We computed Spearman’s rank correlation coef-
ficients between the estimated indicator of the response 
of ART programmes to pretreatment NNRTI resistance 
and each of the seven country-level covariates.
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(grant 5U01-AI069924-05) and Swiss National Science 
Foundation (grant 174281). Study funders had no role in 
study design, data analysis, interpretation of results, or 
writing of the report.































Fig. 2 Model fit for HIV-1 prevalence, ART coverage, mortality, and population size for nine countries of southern Africa, 2000 to 2018. Circles 
represent data obtained from UNAIDS and the World Bank. Lines and shaded areas correspond to model predictions (median posterior and 95% 
credible interval)
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Results
The model reflected the general trends of HIV-1 preva-
lence, ART coverage, AIDS-related mortality and pop-
ulation size in each country for the period 2000–2018 
(Fig. 2). The levels and trends of HIV-1 adult prevalence 
varied by country. Higher prevalences were observed in 
Botswana, Eswatini, and Lesotho and lower, decreas-
ing prevalences in Malawi, Zambia, and Zimbabwe. 
The model fitted the course of AIDS-related mortal-
ity less well, but it captured the magnitude and overall 
trends of mortality in each country. The timing of the 
ART rollout also varied across countries (Figs.  2, 3A). 
It occurred first in Botswana and Namibia, quickly fol-
lowed by most of the other countries, except Mozam-
bique, which rolled out ART later and at a lower rate. 
The peak rate at which patients initiated first-line ART 
was highest in Zimbabwe and Eswatini, and lowest in 
Mozambique and Lesotho (Fig. 3A).
Linking the dynamics of HIV-1 transmission, treat-
ment and mortality to survey data on pretreatment 
NNRTI resistance, the model estimated the rise of 
NNRTI resistance in every country (Fig. 4). There was 
good agreement between the estimated trajectory of 
pretreatment NNRTI resistance between 2000 and 
2018 and the survey data. There were only two outliers 
(defined as survey estimates with confidence intervals 
that did not overlap with modelled estimates). One out-
lying study was from Malawi among persons with acute 
HIV-1 infection [29] and the other one from South 
Africa among sex workers [30]. Model-predicted lev-
els of pretreatment NNRTI resistance in 2018 ranged 
between 3.3% (95% credible interval [CrI] 1.9 to 7.1%) 
in Mozambique and 25.3% (17.9 to 33.8%) in Eswatini 
(Table 1). Large uncertainty intervals reflected the scar-
city of recent survey data in Eswatini, Lesotho, Malawi, 
Namibia, and Zambia.
The absolute prevalence of pretreatment NNRTI 
resistance in 2018 that was estimated not to be attribut-
able to the functioning of the ART programmes ranged 
from 1.5% in Botswana (95%CrI 0.7–2.4) and 1.5% in 
Eswatini (95%CrI 0.5–3.0) to 3.9% (95%CrI 3.1–4.8) in 
Zimbabwe (Table 1). When expressing this prevalence 
in relative terms as a proportion of the overall preva-
lence of pretreatment NNRTI resistance, the propor-
tion was small in Eswatini, Namibia, and the Republic 
of South Africa, ranging from 6% (95%CrI 2–14) in 
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Fig. 3 A Visualising ART rollout: change in the rate of ART initiation 
(per year) between 2000 and 2018 as estimated from the model. B 
Estimates of the fragility index of ART programmes by country. C 
Three-way scatter plot between the posterior samples of: the fragility 
index of ART programmes (y-axis), the proportion of all persons living 
with HIV that initiated ART over the period 2000–2018 (x-axis) and 
the predicted levels of pretreatment NNRTI resistance (PDR) in 2018 
(colour gradient). BWA Botswana, ESW Eswatini, LSO Lesotho, MWI 
Malawi, MOZ Mozambique, NAM Namibia, RSA Republic of South 
Africa, ZMB Zambia, ZWE Zimbabwe
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overall pretreatment NNRTI resistance appears to 
have been strongly influenced by unregulated off-pro-
gramme antiretroviral use in Zambia, Lesotho, and 
Mozambique, ranging from 50% (95%CrI 22–80) in 
Zambia to 64% (95%CrI 26–85) in Mozambique (Table 
1).
Country-specific estimates of ART programmes’ 
fragility regarding pretreatment NNRTI resistance 
showed marked differences across countries (Table  1, 































Fig. 4 Model fit for the prevalence of pretreatment NNRTI resistance in nine countries of southern Africa from 2000 to 2018. Circles represent 
survey results with 95% credible intervals. Lines and shaded areas correspond to model predictions (median posterior and 95% credible interval)
Table 1 Country-level estimates of the main aspects of ART rollout and pretreatment NNRTI resistance in southern Africa
PDR pretreatment drug resistance
The timing of ART rollout refers to the date at which 50% of the maximum treatment rate is reached. The intensity of ART rollout refers to the peak treatment rate per 
year. NNRTI PDR in 2018 is the model-predicted prevalence of NNRTI PDR. Posterior medians with 95% credibility intervals are shown
Country Timing of ART 
rollout, year (95% 
CrI)
Intensity of ART 
rollout, per year 
(95% CrI)
NNRTI PDR in 
2018 (%) (95% 
CrI)
NNRTI PDR in 2018 




NNRTI PDR in 2018 




regarding NNRTI PDR 
of ART programmes 
(95% CrI)
Botswana 2005 (2004–2006) 0.13 (0.12–0.15) 3.7% (2.6–5.6) 1.5% (0.7–2.4) 42% (15–2) 0.01 (0.00–0.11)
Eswatini 2009 (2009–2009) 0.24 (0.18–0.29) 25.3% (17.9–33.7) 1.6% (0.5–3.0) 6% (2–14) 0.64 (0.23–11.8)
Lesotho 2007 (2006–2007) 0.09 (0.082–0.099) 3.9% (1.3–9.8) 2.2% (0.8–4.6) 62% (20–86) 0.01 (0.00–0.70)
Malawi 2009 (2009–2009) 0.22 (0.18–0.28) 8.9% (4.2–24.4) 3.2% (2.1–4.4) 37% (11–72) 0.04 (0.00–1.30)
Mozambique 2009 (2009–2009) 0.11 (0.094–0.13) 3.3% (1.9–6.9) 2.0% (1.2–3.0) 65% (26–84) 0.01 (0.00–0.70)
Namibia 2007 (2006–2008) 0.18 (0.15–0.21) 24.9% (17.8–32.2) 2.1% (0.8–4.7) 8% (3–22) 0.48 (0.15–11.2)
South Africa 2009 (2009–2009) 0.13 (0.12–0.14) 22.7% (18.9–26.1) 1.7% (1.3–2.3) 8% (5–10) 1.21 (0.83–9.84)
Zambia 2008 (2007–2009) 0.17 (0.14–0.21) 6.3% (3.5–13.5) 3.1% (2.1–4.4) 50% (21–80) 0.01 (0.00–0.27)
Zimbabwe 2009 (2009–2009) 0.25 (0.2–0.32) 13.7% (6.8–22.9) 3.9% (3.0–4.7) 28% (15–60) 0.17 (0.00–2.65)
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Fig.  3B). In Botswana, Lesotho, Mozambique, and 
Zambia, fragility was low, with values close to 0, indi-
cating that a rapid switch to second-line ART compen-
sated the number of patients acquiring de novo NNRTI 
resistance during first-line ART. Switching to second-
line ART may thus have prevented the further spread 
of NNRTI resistance in these countries. Conversely, the 
national ART programmes in Eswatini, Namibia, and 
the Republic of South Africa were more fragile, with 
index values ranging from 0.48 (95% CrI 0.16–10.17) 
in Namibia to 1.19 (95%CrI 0.834–6.98) in the Repub-
lic of South Africa. The combination of a high fragility 
of ART programmes regarding pretreatment NNRTI 
resistance and high levels of ART coverage was asso-
ciated with a sharp increase in pretreatment NNRTI 
resistance following the scale-up of ART in these three 
countries (Fig. 3C).
The variation between countries regarding the response 
to pretreatment NNRTI resistance was partly explained 
by differences in country characteristics (Table  2). For 
example, lower fragility regarding pretreatment NNRTI 
resistance was found in countries with higher levels of 
international donor funding (as a proportion of total 
health expenditure). Fragility was higher in countries 
with higher levels of total health expenditure. Of note, we 
did not find evidence of an association between fragility 
regarding NNRTI resistance and the intensity of PMTCT 
programmes.
Discussion
This study provides a detailed analysis of the rise of 
pretreatment NNRTI resistance in nine countries of 
southern Africa for the period 2000 to 2018. We used a 
dynamic transmission model to link the local character-
istics of HIV-1 transmission, ART scale-up and mortality 
at the country level to data from a systematic review of 
pretreatment NNRTI resistance in adults. By includ-
ing all the relevant information from these countries, 
we could examine the dynamics and drivers of pretreat-
ment NNRTI resistance in a region heavily affected by 
the HIV-1 pandemic. In particular, we used the model 
to estimate two country-level indicators of pretreatment 
NNRTI resistance: the proportion of resistance related 
to the unregulated, off-programme use of antiretrovirals, 
and the fragility of national ART programmes regarding 
the threat of resistance.
The increase in pretreatment NNRTI resistance 
between 2000 and 2018 differed across the nine coun-
tries. It was driven by country-level differences in both 
the ART rollout’s timing and intensity and ART pro-
grammes’ fragility. While the evolutionary pressure 
exerted by NNRTI-based first-line ART obtained through 
ART programmes is a necessary condition for the selec-
tion of NNRTI resistance mutations [16], other intricate 
factors influence the level of pretreatment NNRTI resist-
ance in a country. The comparison between Botswana 
and Eswatini illustrates this situation. The early scale-up 
of ART in Botswana and the later but more intense roll-
out in Eswatini led to a similar number of ART initia-
tions relative to the two countries’ populations. Also, the 
model estimated pretreatment NNRTI resistance levels 
attributable to unregulated, off-programme antiretrovi-
ral at around 1.5% for both countries. Yet, the trajecto-
ries of NNRTI resistance differed widely, growing to an 
estimated 25.3% in Eswatini in 2018 compared to 3.8% in 
Botswana. This difference probably resulted from a loss 
of control of the ART programme in Eswatini. Indeed, 
the indicator for the national ART programme’s fragility 
was 0.65 in Eswatini compared to 0.01 in Botswana. Of 
note, the response estimated for the South African ART 
programme was also poor. In South Africa, pretreatment 
Table 2 Country-level characteristics associated with the fragility of ART programmes in southern Africa regarding pretreatment drug 
resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI)
PMTCT, prevention of mother to child transmission
a Spearman’s rank correlation coefficient between the posterior samples of the indicator of vulnerability to pretreatment NNRTI resistance within ART access 
programmes and each covariate (median and 95% credible interval)
b The proportion of pregnant women who received NNRTIs for PMTCT as a proportion of HIV-1 adult prevalence
Country-level covariate Correlationa
Gross national income per capita (US$) 0.28 (− 0.08 to 0.70)
Current health expenditure per capita (US$) 0.53 (0.17 to 0.85)
External donor funding (proportion of current health expenditure) − 0.45 (− 0.80 to − 0.10)
Out-of-pocket expenditure (proportion of current health expenditure) 0.02 (− 0.43 to 0.40)
Rural population (proportion of total population) − 0.17 (− 0.55 to 0.18)
PMTCT (proportion of total  prevalenceb) 0.28 (− 0.15 to 0.63)
Unemployment (proportion of total labour force) 0.22 (− 0.18 to 0.67)
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NNRTI resistance levels were high (estimated at 22.5%) 
despite the ART rollout’s average intensity.
Our study indicates that the countries of southern 
Africa cluster into three groups. In a first group, com-
prised of Botswana, Lesotho, Mozambique, and Zambia, 
pretreatment NNRTI resistance remained below 10% in 
2018, associated with a low fragility of ART programmes. 
The good control exerted within ART programmes pre-
vented the rise of pretreatment NNRTI resistance at the 
population level, even where ART was scaled-up early 
and massively, such as Botswana (Fig.  3A). Residual 
resistance was primarily attributable to unregulated off-
programme antiretroviral use. In contrast, pretreatment 
resistance rose dramatically in the second group, com-
prising Eswatini, Namibia, and South Africa. Off-pro-
gramme antiretroviral use was relatively less important 
in these countries, with the increase mostly driven by 
the combination of a massive scale-up of ART and fragile 
ART programmes. The third group of countries included 
Malawi and Zimbabwe, with pretreatment resistance lev-
els in 2018 around 10%, related to both an intermediate 
level of fragility of ART programmes and some contribu-
tion by off-programme antiretroviral use.
The indicator for the fragility of ART programmes can 
be interpreted as a composite indicator of the level of 
control achieved in a country during ART rollout, cap-
turing the quality of ART delivery [22], including adher-
ence support and virologic monitoring [16, 20, 30, 31]. 
The modification of ART eligibility towards earlier treat-
ment initiation, may also have contributed to drug resist-
ance emergence [15]. Earlier treatment is associated with 
higher levels of non-adherence, and the scale-up of treat-
ment programmes may have strained fragile health sys-
tems [32]. International donor funding was associated 
with a lower fragility of ART programmes. This may be 
explained by the additional, targeted funding of ART pro-
grammes, coupled with the programmatic support and 
monitoring by international donors. Conversely, higher 
levels of total health expenditure was associated with a 
worse response of ART programmes to the threat of pre-
treatment NNRTI resistance. The rapid scale-up of ART 
in some countries may have overburdened the health sys-
tem and affected patient management. Although PMTCT 
has been proposed as an essential driver of NNRTI resist-
ance [22], we found little evidence for an association 
between PMTCT coverage and fragility. This may be due 
to the relatively homogeneous uptake of PMTCT across 
countries of the region.
Our study’s main strength is the application of a 
dynamic transmission model, which describes how the 
emergence of NNRTI drug resistance, together with 
the dynamics of HIV-1 transmission, ART scale-up and 
mortality produced disparate trends in NNRTI resist-
ance across southern Africa. Fitted to country-level 
data using Bayesian inference, the model allowed for 
the full propagation of uncertainty and relied on a few 
assumptions. We focused on mechanisms that could be 
informed by data available for all countries during the 
period of interest. While the model captured the main 
trends of the HIV-1 epidemic in each country, its rela-
tively simple structure ignored some dimensions such 
as age, gender, acute infections and disease progres-
sion. However, adding more dimensions would have 
increased the complexity of a model that is already 
computationally expensive to fit due to its hierarchi-
cal nature. These considerations meant that we did not 
consider data on previous exposure to PMTCT, off-pre-
scription use of ART or undocumented treatment dis-
continuation. Rather, these mechanisms were estimated 
together by considering the proportion of pretreatment 
NNRTI resistance that is unrelated to the ART rollout.
Another limitation concerns the analysis of country-
level data, exposing the results to ecological bias, and 
ignoring potential within-country heterogeneity. This 
choice was dictated by the scale of available data and 
the fact that HIV-related health policies are imple-
mented at the national level. More data on NNRTI 
resistance, treatment adherence, previous exposure 
to ART, loss to follow-up, virological failure, and ART 
coverage for first and second-line treatment, collected 
systematically at the country level or at a lower scale, 
would be necessary to improve the precision of the 
estimates. A last limitation concerns the analysis of the 
characteristics associated with the fragility of national 
ART programmes. This analysis was exploratory and 
based on a small number of countries and indicators.
In conclusion, the rollout of ART in southern Africa 
was followed by increasing levels of pretreatment 
NNRTI resistance. This increase has been heterogene-
ous across countries of the region. The between-coun-
try comparison shows that resistance can be controlled 
despite high levels of ART coverage. Our results sug-
gest that the fragility of ART programmes regard-
ing pretreatment NNRTI resistance is associated with 
features of the healthcare system at the national level. 
Further research is needed to determine more precisely 
what organisational features allowed the control of 
pretreatment NNRTI resistance in countries like Bot-
swana, Lesotho, Mozambique, and Zambia. Our results 
suggest that resistance, once emerged, can be con-
trolled even if the drug is made used very widely. They 
have implications for the ongoing rollout of dolutegra-
vir in southern Africa. Concerns about drug resistance 
should not lead to restrictions of the use of dolutegra-
vir, which has a high genetic barrier to resistance [33] 
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or the use of NNRTIs where it continues to be appro-
priate, but rather to interventions aimed at controlling 
the emergence and spread of resistance.
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